Exclusive: Universal beat Disney as Hollywood’s maker of the most expensive movie of all time

Universal Pictures spent $658.8 million on "Jurassic World: Dominion," making it the most expensive movie ever and topping Disney’s $638.9 million "The Force Awakens." After a $127.8 million U.K. reimbursement, Universal’s net outlay fell to $531 million, and the film grossed about $1 billion at the box office. The article is primarily about film production economics, U.K. tax incentives, and the potential impact of proposed U.S. tariffs on foreign-made movies.

Analysis

The important signal is not that one tentpole got expensive, but that the U.K. tax-credit machine has effectively subsidized Hollywood’s appetite for scale and schedule slippage. That creates a perverse incentive: studios can rationally overinvest in location-heavy, high-touch productions because part of the overrun is socialized through reimbursement, while the economic pain is delayed and partially obscured until later filings. For exhibitors and content owners, the broader implication is that franchise economics are being supported by foreign policy, not just box office discipline.

The biggest second-order beneficiary is Marriott and the broader premium hospitality set. Pandemic-era filming turned hotels into quasi-production infrastructure, and that model is sticky: if studios expect future U.K. shoots to be preserved for tax efficiency, they’ll keep booking long-duration luxury lodging, transport, and security blocks. That supports ancillary revenue in a way the market may underwrite only as transient travel demand rather than recurring production demand.

The key risk catalyst is policy reversal, not consumer demand. A U.S. tariff on foreign-produced films would not just reprice studio margins; it would force a reconfiguration of production geography over a 12-24 month horizon, with near-term disruption to release calendars and a likely step-up in domestic labor and stage costs. If the tariff remains only rhetorical, the current regime likely persists because the U.K. subsidy plus established infrastructure still beats onshore U.S. production economics for large effects-heavy franchises.

The contrarian view is that the headline “most expensive movie” is less relevant than the fact that the studio likely still cleared an acceptable franchise-level return once tax credits and downstream monetization are included. The market may be overestimating the deterrent effect of capex headlines on future sequels; for a durable IP library, the real question is not cost per film but marginal ROI of the next installment, which still looks protected by global distribution and ancillary monetization.

Key Decisions for Investors

• Long MAR vs short DIS for 3-6 months: Marriott has a cleaner leverage to production-related premium room demand and less direct exposure to theatrical ROI scrutiny; Disney faces higher headline risk if tariff rhetoric turns into policy and forces cost inflation across its franchise slate.
• Buy a 6-12 month call spread on MAR (or equivalent hospitality proxy) into any studio production pickup headlines: the asymmetric thesis is sustained high-ADR booking behavior from film crews, with limited downside unless broader travel weakens.
• Keep DIS on a tactical short/underweight against AMZN/NFLX for 6-9 months: theatrical cost inflation is a margin drag for legacy studio content, while streamers are better positioned to absorb high fixed content costs through global subscription monetization and flexible release windows.
• Event-driven hedge: if tariff language re-accelerates, buy short-dated DIS puts or a DIS/AMZN pair trade for 1-3 months; upside to the trade comes from immediate multiple compression on foreign-location dependence, with risk capped if rhetoric fades again.
• Monitor UK film incentive policy as a catalyst: any sign of AVEC tightening would be a negative for studio filming in the U.K. and a positive for domestic production services; if that emerges, rotate out of studio beneficiaries and into U.S.-based production infrastructure names.